---
layout: default
title: Activated Charcoal Alfalfa American Ginseng Aspara
parent: 僅模型預測 (L5)
nav_order: 161
evidence_level: L5
indication_count: 0
---

# Activated Charcoal Alfalfa American Ginseng Aspara
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Complex (25 Components): TxGNN Repurposing Analysis Not Applicable

## One-Sentence Summary

This entry contains a 25-ingredient complex product comprising herbs, animal glandulars, homeopathic agents, and botanical extracts — none of which map to a standard pharmaceutical drug entity.
TxGNN could not generate any repurposing prediction, as the product has no DrugBank identifier, no approved indication in any surveyed registry, and no processable mechanism of action.
At this time, **there is insufficient structured data to conduct a meaningful repurposing evaluation.**

---

## Quick Overview

| Item | Content |
|------|---------|
| Product Type | Multi-ingredient complex (25 components: herbal / glandular / homeopathic) |
| Original Indication | None recorded |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | Below L5 — no model output available |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why Is No Prediction Available?

TxGNN operates by linking a drug's DrugBank node to disease nodes in a biomedical knowledge graph. For a prediction to be generated, the product must have:

1. A resolvable DrugBank ID, or at minimum a single active pharmaceutical ingredient (API) that can be mapped, and
2. At least one approved indication that anchors the drug in the disease graph.

This product contains 25 heterogeneous components spanning four distinct therapeutic traditions:

| Category | Examples from This Product |
|----------|---------------------------|
| Herbal / botanical | Alfalfa, American Ginseng, Berberis Vulgaris, Garlic, Gentiana Lutea, Avena Sativa, Passiflora Incarnata, Solidago Virgaurea, Scrophularia Nodosa |
| Glandular (animal organ) | Beef Kidney, Beef Liver, Bos Taurus Adrenal Gland, Colon, Lymph Vessel, Pancreas |
| Homeopathic | Histamine Dihydrochloride, Phosphorus |
| Gemmotherapy / Bach flower | Carpinus Betulus Flower, Malus Sylvestris Flower, Ribes Nigrum Flower Bud, Juniperus Communis Stem |
| Other | Activated Charcoal, Asparagus, Lactic Acid DL, Tribasic Calcium |

None of these components carry a DrugBank ID as a combination, and the product is not registered in the US FDA database. The knowledge graph has no anchor point from which to propagate a repurposing signal.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this combination product.

---

## Literature Evidence

Currently no related literature available for this specific multi-ingredient combination.

---

## US Market Information

This product has **0 recorded authorizations**. It is not marketed in the United States under any NDA, BLA, or OTC monograph found during the query performed on 2026-03-24.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note for evaluators:** Several individual components in this product carry known safety signals that would require independent assessment before any clinical use:
> - **Berberis Vulgaris** (barberry): may inhibit CYP3A4; contraindicated in pregnancy
> - **American Ginseng**: may interact with warfarin and diabetes medications
> - **Activated Charcoal**: may reduce absorption of co-administered drugs
> - **Histamine Dihydrochloride** (homeopathic dilution): regulatory status varies by jurisdiction
>
> A component-by-component DDI and contraindication review would be required before any further evaluation.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
TxGNN cannot process this product because it lacks a DrugBank identifier, an approved indication, and a unified mechanism of action — the three prerequisites for knowledge-graph-based repurposing analysis. The product does not represent a single pharmaceutical entity and is not amenable to the current pipeline in its present form.

**To proceed, the following is needed:**

- **Identify the intended API:** Determine which single active ingredient(s) this product is intended to deliver therapeutically, and resubmit each as a separate drug entry.
- **Obtain DrugBank IDs:** Map individual components (e.g., Berberine from Berberis Vulgaris, Allicin from Garlic) to DrugBank nodes for graph traversal.
- **Establish an original indication:** Without a documented therapeutic claim, the pipeline has no starting node in the disease graph.
- **Regulatory classification:** Clarify whether this product is regulated as a dietary supplement, homeopathic product, or investigational combination drug in the target market — this determines which evidence standards apply.
- **Component-level safety review:** Commission individual DDI checks for the pharmacologically active components (Berberine, Garlic allicin, Ginseng ginsenosides, Passiflora flavonoids) before any clinical consideration.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

